Synopsis: With a pre market cap of Rs 6,495.20 Cr , Corona Remedies IPO is expected to list on 15 Dec 2025 with the allotment of shares happening on 11th Dec 2025, let check how to check the allotment status as well as financial health of the firm.
Corona Remedies Limited a pharmaceutical company engaged in developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management and more recently launched its IPO which garnered huge response being subscribed by a whooping 144x.
It offered shares at a price band set at Rs 1008 to Rs 1062 per share, with face value of Rs. 10 per and the lot size for an applicant at 14shares. The issue was entirely an offer for sale of Rs 655.37 crore. The issue is managed by JM Financial Ltd., IIFL Capital Services Limited and Kotak Mahindra Capital Company Limited as the book-running lead manager, with Bigshare Services Pvt.Ltd. serving as the registrar.
Timeline of the IPO
The Corona Remedies IPO was opened on December 8, 2025, and closed on December 10, 2025, and the cut-off time for UPI mandate confirmation was set at 5 PM on December 10.
The tentative allotment date is December 11, 2025, followed by the initiation of refunds and credit of shares to Demat accounts on December 12, 2025. The IPO is expected to list on December 15, 2025 on both NSE and BSE.
Steps to check IPO allotment
- Step 1: Go to the Registrar website, which is Bigshare Services Pvt.Ltd for this IPO: https://www.bigshareonline.com/ipo_allotment.html
- Step 2: Select the IPO company name.
- Step 3: Enter your PAN/Application/Beneficiary number in the section, and you can view the status of your IPO allotment.
GMP
Corona Remedies IPO’s latest GMP stands at Rs 291, updated on December 11, 2025, at 04:00 AM. With a price band cap of 1062.00, the IPO’s estimated listing price comes to Rs 1353 (cap price + GMP). This implies a potential listing gain of 27.78 percent per share.
IPO Lot size
Corona Remedies IPO requires a minimum bid of 14 shares, and investors can apply in multiples of this lot size. For retail investors, the minimum application is 1 lot (14 shares) amounting to Rs. 14,868, while the maximum permissible retail application is 13 lots (182 shares) totaling Rs. 1,93,284.
For High Net-worth Individuals (HNIs), the S-HNI category begins at 14 lots with 196 shares requiring an investment of Rs. 2,08,152, and can go up to 67 lots (938 shares) totaling Rs. 9,96,156. The B-HNI category starts from 68 lots (952 shares) with a minimum investment of Rs. 10,11,024.
Objectives of the IPO
The RHp stated that the company does not have any specific objectives that is to be announced, being an offer for sale completely, the proceeds of the IPO will
Completely go to the promoters who have sold the stake.
About the company
Corona Remedies is an India-focused branded pharmaceutical formulation company specializing in the development, manufacturing, and marketing of products across women’s healthcare, cardio-diabetes, pain management, urology, and other key therapeutic areas.The company is headquartered in Ahmedabad.
As of June 30, 2025, the company’s diverse portfolio includes 71 brands across therapeutic areas like women’s healthcare, cardio-diabeto, pain management, urology, and multispecialty pharmaceuticals (including vitamins/minerals/nutrition, gastrointestinal, and respiratory).
Anchor Investors List
Anchor investors subscribed to the company’s shares at a bid price of Rs 1,062. Among them, SBI Healthcare Opportunities Fund received 141,274 equity shares, accounting for 7.7 percent of the anchor allocation. ICICI Prudential Quality Fund was allotted the same number of shares, with both investors committing Rs 15,00,32,988 each.
Other prominent anchor investors include DSP Healthcare Fund, Invesco Trustee Pvt Ltd, and Franklin India Large & Mid Cap Fund. Each of these investors was allotted 116,970 equity shares, with each of them representing 6.38 percent of the anchor portion, with an investment of Rs 12,42,22,140 each.
Financials of the company
Corona Remedies financial performance shows steady growth over the recent years, highlighted a YoY revenue from operations growth of 17.9 percent rise into Rs. 1196.4 cr in FY25 and a 65 percent jump in profit after tax (PAT) to Rs. 149.4 cr in FY25.
As of June 30, 2025, the company reported total assets of Rs. 1012.3 cr, reflecting continued expansion from Rs. 929.8 crore in March 2025 and Rs. 830.5 crore in March 2024.
The company’s financial position has also strengthened, with reserves rising to Rs. 545.8 cror, and the borrowings for June 2025 have also increased to Rs.106.65 crore, indicating an approach to leveraging while supporting expansion. The key performance indicators (KPIs) of FY 2025 showed an ROE of 27.50 percent, ROCE of 41.32 percent, and a healthy RoNW of 24.65 percent.
-Adithya Menon
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
